Comparative Pharmacology
Head-to-head clinical analysis: DRISDOL versus ZEMPLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRISDOL versus ZEMPLAR.
DRISDOL vs ZEMPLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drisdol (ergocalciferol) is a vitamin D2 analog that increases intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and stimulates bone mineralization by binding to vitamin D receptors, which regulate gene expression.
Vitamin D receptor agonist; binds to vitamin D receptors, regulating gene expression of calcium-binding proteins and cellular proliferation/differentiation.
50,000 IU orally once weekly for 8 weeks, then 50,000 IU orally once monthly for maintenance.
0.04-0.1 mcg/kg IV three times weekly; titrate to serum calcium. Oral: 1-2 mcg daily or 0.5-1 mcg three times weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 19–48 hours after a single oral dose, with clinical context: repetitive dosing increases half-life due to accumulation in adipose tissue, leading to a functional half-life of weeks to months for vitamin D stores.
Terminal elimination half-life is 5–7 hours in healthy subjects; prolonged to 14–21 hours in patients with chronic kidney disease stage 5 on hemodialysis, reflecting reduced clearance.
Primarily excreted via bile into feces (~90%), with renal excretion accounting for the remainder (~10%). Biliary excretion of metabolites is the major route, with enterohepatic recycling contributing to prolonged elimination.
Primarily hepatobiliary (74% of absorbed dose recovered in feces as parent drug and metabolites); renal excretion accounts for approximately 16% (primarily as metabolites).
Category C
Category C
Vitamin D Analog
Vitamin D Analog